Better Coronavirus Stock: Inovio Pharmaceuticals or GlaxoSmithKline?
Drugmakers big and small are pulling out all the stops to develop treatments and vaccines for novel coronavirus disease COVID-19. Two that threw their hats into the ring early are Inovio Pharmaceuticals (NASDAQ: INO) and GlaxoSmithKline (NYSE: GSK).
Inovio is only a fraction of the size of GlaxoSmithKline but appears to be ahead with respect to advancing an experimental coronavirus vaccine to clinical testing. Does this lead make Inovio a better stock to buy right now -- or is GSK the smarter pick?
Image source: Getty Images.
Source Fool.com
